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Abstract
Background: Valproic acid, a widely used anticonvulsant drug, is a potent teratogen resulting in various congenital
abnormalities. However, the mechanisms underlying valproic acid induced teratogenesis are nor clear. Recent
studies indicate that histone deacetylase is a direct target of valproic acid.
Methods: In the present study, we have used histological analysis and RT-PCR assays to examine the cardiac
abnormalities in mice treated with sodium valproate (NaVP) and determined the effects of NaVP on histone
deacetylase activity and the expression of heart development-related genes in mouse myocardial cells.
Results: The experimental data show that NaVP can induce cardiac abnormalities in fetal mice in a dose-
dependent manner. NaVP causes a dose-dependent inhibition of hitone deacetylase (HDAC) activity in mouse
myocardial cells. However, the expression levels of HDAC (both HDAC1 and HDAC2) are not significantly changed
in fetal mouse hearts after administration of NaVP in pregnant mice. The transcriptional levels of other heart
development-related genes, such as CHF1, Tbx5 and MEF2, are significantly increased in fetal mouse hearts treated
with NaVP.
Conclusions: The study indicates that administration of NaVP in pregnant mice can result in various cardiac
abnormalities in fetal hearts, which is associated with an inhibition of histone deacetylase without altering the
transcription of this enzyme.
Introduction
Valproic acid (VPA) has been widely used as an antic-
onvulsant drug for over 40 years. It is unusual among
anticonvulsants in that it has broad activity against
both generalized and partial seizures [1]. VPA is rela-
tively free of side-effects compared to other anticon-
vulsants and is routinely used in epileptic patients [2].
However, studies have indicated a potent teratogenicity
of valproic acid, or sodium valproate. VPA has been
associated with a variety of major and minor congeni-
tal malformations, including a 20-fold increase in
neural tube defects, cleft lip and palate, cardiovascular
abnormalities, genitourinary defects, and autism.
Furthermore, there is an established relationship
between VPA dose and adverse outcome [3]. It has
been suggested that poly-therapy treatment in epileptic
pregnant women increases the risk of teratogenicity in
offspring. Maternal VPA use during pregnancy is asso-
ciated with adverse fetal outcome including cardiac
defects and skeletal malformations [4]. The pattern of
major malformations, minor dysmorphic features, and
neurological abnormalities seen in children prenatally
exposed to VPA is referred to as the fetal valproate
syndrome [4]. A case study reported a complex cardiac
defect with hypoplastic right ventricle in a fetus with
valproate exposure [5]. Many animal studies also con-
firm the teratogenicity of VPA in the animals exposed
to the drug [6-8].
Despite its long-standing usage, the mechanism of the
anticonvulsant activity of valproate is still controversial.
The mechanism underlying VPA-induced side effects
and teratogenicity is also unknown. Recently, VPA has
been defined as a novel class of histone deacetylase
(HDAC) inhibitors, modifying chromatin structure and
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we have applied sodium valproate (NaVP) to pregnant
mice and investigated cardiac malformation during
development. Our results indicate that administration of
NaVP in pregnant mice can result in various cardiac
abnormalities in fetal hearts, which is likely associated
with an inhibition of histone deacetylase without alter-
ing the transcription of this enzyme.
Methods
Animals
The C57/B6 mice used in this study were maintained as
a pathogen-free colony at Flori d aA t l a n t i cU n i v e r s i t ya t
Boca Raton, FL. Wild-type (WT) littermates were used
as controls in the present study. This investigation was
in accordance with the protocols approved by the Insti-
tutional Animal Care and Use Committees at Florida
Atlantic University. To obtain pregnant mice, female
mice were mated with male breeders and inspected
every morning for 4 days. Females showing avaginal
plug were immediately separated from the males and
the morning was denoted as day 1. The pregnant mice
were intraperitoneally injected with various amounts of
sodium valproate (0, 200, 400, 600 and 700 mg/kg body
weight) (Sigma, USA) on day 7 and control group were
injected with same volume saline.
Histology
Fetal hearts isolated from the newborns of sodium
valproate (NaVP) treated mice and the saline treated
control mice were washed in cold PBS solution. The
hearts were immersed in 10% formalin solution for at
least 2 h. The hearts were dehydrated progressively in
50% ethanol for 1 h, 70% ethanol for 1 h, in 95% etha-
nol 1 h and then in 100% ethanol overnight. After
xylene treatment, the hearts were embedded in 100%
paraffin. Fixed hearts were sectioned into 5-μmt h i c k
slices and stained with hematoxylin and eosin. The
slides were viewed under an Olympus SZX12 inverted
microscope and the images were captured by an Olym-
pus U-CMAD3 camera.
Mouse myocardium culture
Mouse myocardium separati o na n dc u l t u r ew e r ec a r -
ried out using a Neomyt Isolation System for Neonatal
Rat/Mouse Cardiomyocytes (Cellutron, MD, USA)
according to the protocol from the manufacturer.
Briefly, the ventricles from 5 to 7 neonatal mouse
hearts (1-3 days after birth) were collected and washed
with cold B1. The ventricular tissues were diced and
digested for 12 min at 37°C in dissociation buffer B2 +
EC. After digestion, the cell pellet was resuspended in
B3 plus 50% NS media. The dissociations were
repeated 6 times until all tissues were dispersed into
single cells. The cells were collected by centrifuging at
1,000 g for 1 min and resuspended in NS media con-
taining 10% of bovine calf serum. Preplating was per-
formed to eliminate the nonmyocytes by incubating
the culture dishes at 37°C for 30 min. After 30 min,
the cell suspension was plated into 24-well cell culture
plates. The cells were cultured for 24 h prior to drug
treatment. The characterization of neonatal cardiac
myocytes was performed as described in our previous
studies [12]. The cardiac myocyte purity of a 48-hour
culture was about 80-85% as measured by immunoflur-
escent staining with monoclonal antibodies against
mouse myosin heavy chain. Most of the cultured neo-
natal cardiac myocytes contracted regularly under
microscopic observation and some cells formed syn-
chronously and spontaneously contracting myocardial
tissue.
HDAC activity assay
The cultured mouse neonatal cardiac myocytes
(described above) were treated with 0 μM, 10 μMa n d1
mM of NaVP for 8 hours before assays. The HDAC
activity in NaVP treated and control culture was deter-
mined using a HDAC Fluorometric Cellular Activity
Assay Kit (Biomol, PA, USA) according to the manufac-
turer’s instructions. Briefly, the culture media in treated
and control cardiac myocytes were replaced with 200
μl/well of fresh media containing 200 μM Fluor de Lys
Substrate (KI-104). Plates were incubated at 37°C for 1
hour, with each condition represented in triplicate. To
terminate HDAC activity and begin development of the
fluorescence signal, 200 μl per well of the 1× Developer
was added and mixed by up and down pipetting. The
mixtures were incubated for an additional 15 min at 37°
C, and fluorescence was measured using a SpectraMax
M5
e Microplate Reader (Molecular Devices, CA, USA),
with an excitation wavelength of 360 nm and an emis-
sion wavelength of 460 nm.
Quantitative polymerase chain reaction
The treated and control pregnant mice were sacrificed
on day 16 and fetal hearts were isolated and pulverized
in liquid nitrogen. Total RNA was extracted using a Tri-
Reagent (Sigma, MO, USA) according to the manufac-
turer’s instructions. Residual genomic DNA was
removed by treatment with 2 units of rDNase I
(Ambion, TX, USA) at 37°C for 1 hour. The DNA-free
RNA samples were re-extracted with an equal volume
of Tri-Reagent. The aqueous phase containing RNA was
precipitated with isopropyl alcohol, and the RNA was
dissolved in RNase-free water. 2 μg of extracted total
RNA was primed by random primers and reverse tran-
s c r i b e du s i n gaT h e r m o S c r i p tR T - P C RS y s t e m( I n v i t r o -
gen, CA, USA) at 55°C for 50 min, and then terminated
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C prior to PCR amplification. The specific primers were
designed using the Primer Express computer program
(Perkin Elmer Applied Biosystems, CA, USA) and all
primer sequences were designed to span at least one
intron to diminish residue genomic DNA interference.
The primer sequences, product lengths and amplifica-
tion conditions are summarized as follows:
HDAC1, FW: GGGCACCAAGAGGAAAGT; RV:
CTCCCGTGGACAACTGA
HDAC2, FW: GACATATGAGACTGCAGTTGC; RV:
ACCTCCTTCACCTTCATCCTC
Nkx2.5, FW: CACCCACGCCTTTCTCAGTC; RV:
CCATCCGTCTCGGCTTTGT
GATA4, FW: CTGTCATCTCACTATGGGCA; RV:
CCAAGTCCGAGCAGGAATTT
Tbx5, FW: CAAACTCACCAACAACCACC; RV:
GCCAGAGACACCATTCTCAC
MEF2C, FW: TAATGGATGAGCGTAACAGACAGG;
RV: ATCAGACCGCCTGTGTTACC
CHF1, FW: GACAACTACCTCTCAGATTATGGC;
RV: TAGCCACTTCTGTCAAGCACTC
b-actin, FW: CCACTGCCGCATCCTCTTCCTC;
RV: CAGCAATGCCTGGGTACATGGTG
For semi-quantification, PCR reactions were carried in
1 × PCR buffer (Invitrogen, CA, USA), 1.5 mM MgCl2,
200 μMd N T P ,0 . 5μMo fe a c hp r i m e r ,0 . 2Uo fP l a t i -
num Taq DNA polymerase (Invitrogen) and 2 μlo f
cDNA template in a total volume of 50 μl. A MasterCy-
cler gradient PCR system (Eppendorf, Hamburg, Ger-
many) was programmed as 1 cycle at 95°C for 2 min, 1
min at 94°C followed by 50 sec at optimized annealing
temperature and then followed by 1 min at 72°C for 35
- 45 cycles, and 10 min at 72°C for 1 cycle. b-actin was
used as the reference gene. 10 μl of the PCR reaction
was resolved in 1.2% agarose gel in TBE buffer, stained
with Ethidium Bromide for 1 h and then photographed
or scanned. Quantification of amplified products was
performed by QuantityOne software (Bio-Rad, PA,
USA). The intensities of the interests mRNA bands
were normalized relative to that of b-actin bands by
dividing the former by the b-actin product densities.
Real-time PCR were performed in 96-well optical PCR
plates using a Stratagene Mx3005P Real-Time PCR Sys-
tems (Stratagene, CA, USA) to confirm the expressions
according to the manufacturer’s instructions. Reactions
were conducted in a 20 μl volume of reaction mix with
2 μlc D N A ,0 . 5μM primers, the optimized MgCl2 (1.5-
3.0 mM) and 1× Fast Master SYBR Green I (Roche, IN,
USA). Assays were duplicated and the specificity of PCR
products was checked with a high-resolution gel electro-
phoresis showing a single product band with the desired
sequence length. The analyses of relative mRNA expres-
sion were carried out using the 2
-ΔΔCt method [13].
Statistical analyses
Statistical significance was determined by ANOVA fol-
lowed by post hoc Tukey’s multiple comparison test.
Statistical significance was set at P < 0.05.
Results
The results from teratogenesis analysis indicated that
the average fetus number per pregnant female mouse
was not significantly different between the treatment
group with NaVP and the control groups, however, the
fetal death and fetal resorption rates were significantly
higher in all NaVP treated groups (D6 to D9) compared
to the control groups (Table 1). In addition, NaVP treat-
ment caused a significant increase of cardiac abnormal-
ity rate in the treatment groups compared to the
controls, with the highest cardiac abnormality rate in
the group treated with NaPV on gestation day 7 (D7)
(Table 1). Cardiac abnormalities in fetal mice exposed
to NaVP showed a dose-dependent pattern with the
highest rate in the group treated with 700 mg/kg NaVP
in our assay conditions (Figure 1). Histological examina-
tion of cardiac sections from both treated and control
groups indicated that the cardiac abnormalities were
characterized primarily by interventricular septal defects
and by atrial septal defects as well as other types of con-
genital heart diseases. Figure 2 shows representative car-
diac sections after HE staining from the control group
(Figure 2A) and the NaVP treated group (Figure 2B).
F i g u r e2 Bc l e a r l ys h o w sat i s s u el o s si ni n t e r v e n t r i c u l a r
septum (IVS), as indicated by an arrow, between the
right ventricle (RV) and the left ventricle (LV) of the
heart, whereas the IVS in the heart of the control group
is intact without any damage (Figure 2A).
Since acetylation of histones H3 and H4 in mamma-
lian cell nucleus plays a critical role in gene expression
and organ development, we further examined the effect
of NaVP on histone deacetylase (HDAC) in cultured
neonatal mouse cardiac myocytes. Figure 3 shows that
NaVP inhibits HDAC activity in mouse cardiac myo-
cytes in a dose-dependent manner. Even at a low dose
of 10 μM, NaVP caused a significant inhibition of
HDAC activity in these cells (P < 0.05)(Figure 3).
We carried out quantitative RT-PCR experiments on
fetal hearts to determine the mechanism of NaVP-
induced HDAC inhibition. The mRNA expression of
various genes in the heart was determined including
HDAC1, HDAC2 and other heart development related
genes, such as GATA4, CHF1, Tbx5, MEF2C, etc. Fig-
ure 4 shows that no significant changes are observed in
the expression levels of HDAC1, HDAC2, GATA4,
Nkx2.5 between NaVP-treated groups and the control
groups. The data indicate that the inhibitory effect of
NaVP on HDAC activities is unlikely to act through the
transcriptional inhibition of this gene. In addition, our
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increased in other tested genes, such as CHF1, Tbx5
and MEF2C in fetal hearts from NaVP-treated groups
compared to that of the controls (Figure 4).
Discussion
Valproic acid was considered a relatively side-effect free
compound and was routinely used in epileptic patients,
in come cases successfully for decades [2]. However, its
side-effect, especially its teratogenecity is attracting
more and more attention. The name of the fetal valpro-
ate syndrome indicates that multiple organ malforma-
tions have been seen in children prenatally exposed to
valproic acid [4]. In our study, we further confirm the
teratogenetic effects of NaVP on fetuses when pregnant
mice are exposed to this compound during the gestation
days of organ formation, i.e. gestation day 6 to day 9 in
mice. A hypoplastic right ventricle has been reported in
a fetus with valproate exposure [5]. Our study indicates
that prenatal NaVP exposure causes significant cardiac
abnormalities, in particular, interventricular septal
defects in the heart.
Histones form the protein core of nucleosomes, the
DNA/protein complexes, which are the subunits of
eukaryotic chromatin. The chromatin histone acetyla-
tion/deacetylation plays a critical role in the protein
gene expression and organogenesis [14]. The balance of
histone acetylation/deacetylation is controlled by two
key groups of enzymes: histone acetyltransferases
(HATs) catalyze the acetylation of specific histone lysine
residues and histone deacetylases (HDACs) are responsi-
ble for hydrolytic removal of these acetyl groups [15-17].
Histone hyperacetylation correlates with an open,
decondensed chromatin structure and gene activation,
while hypoacetylation correlates with chromatin conden-
sation and transcriptional repression. Consistent with
this, HATs have been shown to associate with several
transcription activators and some transcription activa-
tors have been found to have intrinsic HAT activity
[15-17]. Conversely, HDACs are found to associate with
transcription repression complexes [18].
Table 1 Fetal loss and cardiac abnormality in NaVP exposed dams
Treatment (Gestation) No. of dams Total No. of
Live fetuses (fetus/dam)
N. of death or resorption Cardiac abnormalities
No. in live fetus %
Day 6
Control 10 163 (16.3) 2 1 0.60
Treated 20 148 (7.4)* 63* 13 8.70*
Day 7
Control 12 148 (12.3) 3 1 0.67
Treated 24 162 (6.75)* 90* 34 20.90*
Day 8
Control 10 147 (14.7) 3 0 0.00
Treated 20 132 (6.6)* 78* 13 9.80*
Day 9
Control 10 149 (14.9) 1 1 0.68
Treated 20 142 (7.1)* 60* 9 6.30*
Pregnant female mice received a one-time injection (i.p.) of NaVP (700 mg/kg body weight) on gestation day as indicated. The fetuses were examined on
gestation day 19 after sacrifice of the pregnant mice as described in Materials and Methods.
* P < 0.05 compared to controls.
Figure 1 Dose-dependent cardiac abnormalities in fetal mice
prenatally exposed to NaVP. Cardiac abnormality rate increased
significantly in fetal mice (gestation day 19) after prenatal exposure
to NaVP (pregnant female mice received a one-time injection of
NaVP on gestation day 7 at various doses). The cardiac abnormality
caused by NaVP shows a dose-dependent pattern with the highest
rate in the group of a treatment dose at 700 mg/kg body weight.
* P < 0.05 vs. control without sodium valproate treatment.
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ate induced cardiac malformation, we performed experi-
ments to determine the effect of valproate on histone
deacetylase activity. Our data indicate that valproate can
significantly inhibit HDAC activity in mouse cardiac
myocytes exposed to NaVP. This result is consistent
with a recent report that valprotic acid is defined as a
novel class of HDAC inhibitors inducing differentiation
of transformed cells [9]. The mechanism underlying the
inhibitory action of valproate on HDAC is still
unknown. According to our experimental data, we
believe that valproate does not inhibit HDAC activities
through the intervention of the transcription of HDAC
genes. More likely, valproate inhibits HDAC activities
directly by binding with the active site of the enzyme as
other HDAC inhibitors do [19-21].
Although no significant changes were observed in the
expression levels of HDACs, GATA4 and Nkx2.5 in
fetal hearts exposed to NaVP, some significant changes
were observed in the expression levels of several heart
development-related transcription factors such as CHF1,
MEF2C and Tbx5 in fetal hearts exposed to NaVP.
CHF1 is a member of the cardiovascular basic helix-
loop-helix factor family and plays an important role in
regulation of ventricular septation in mammalian heart
development [22,23]. MEF2C is a member of the MEF2
family of transcription factors that bind a conserved A-
T-rich DNA sequence associated with most cardiac
muscle structural genes and are expressed in cardiogenic
precursor cells and differentiated cardiac myocytes dur-
ing embryogenesis [24,25]. Tbx5 is a T-box transcription
factor that plays a critical role in cardiac development.
Tbx5 is expressed in the developing heart in vertebrate
embryos during critical stages of morphogenesis and
patterning. In human, mutations in the Tbx5 gene have
been associated with Holt-Oram syndrome, which is
characterized by developmental anomalies in the heart
and forelimbs [26,27]. The expression pattern of Tbx5
in the heart is very interesting. It is uniformly expressed
Figure 2 Histological examination of cardiac sections from fetal hearts with or without exposure to NaVP. Cardiac sections were
examined from the fetal mice (gestation day 19) with or without prenatal exposure to NaVP (exposure group, the pregnant female mice
received a one-time injection intraperitoneally of NaVP on gestation day 7 at a dose of 700 mg/kg body weight; control group, the pregnant
female mice received a one-time injection of saline solution at the same time). (A) A representative cross section image of normal fetal hearts
from the control groups. (B) A representative image of the fetal hearts from the NaVP treated group showing an interventricular septal
interruption indicated by an arrow. RV, right ventricle; LV, left ventricle; IVS, interventricular septum.
Figure 3 Inhibition of NACD activities by NaVP in cardiac
myocytes. HDAC activities were measured as described in Materials
and Methods and HDAC activities were presented as absorbance
fluorescent unit (AFU). Values are Mean ± SEM from 3 separated
experiments. * P < 0.05 vs. control without sodium valproate
treatment.
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developing heart. With the development of the heart,
Tbx5 is asymmetrically expressed in the heart. Expres-
sion of Tbx5 in the ventricular septum is restricted to
the left side and is contiguous with left ventricular free
wall expression. Some studies indicate that these pat-
terns of Tbx5 expression provide an embryologic basis
for the prevalence of atrial and ventricular septal defects
observed in patients with Holt-Oram syndrome [28].
Liberatore et al generated transgenic mouse embryos
that over-express Tbx5 throughout the primitive heart
tube and found a significant loss of ventricular-specific
gene expression and retardation of ventricular chamber
morphogenesis in these embryos, indicating that Tbx5
plays an essential role in early heart morphogenesis and
chamber-specific gene expression [29]. However, it
remains unclear for the moment as to why the expres-
sion of these genes is enhanced by valproate and what
the relationship is between valproate-mediated increase
of these gene expression and valproate-induced cardiac
malformation during heart development. Further studies
are on the way to explore the down-stream activities
after the valproate-enhanced expression of these tran-
scriptional factors in the developing heart.
Conclusion
Our data indicate that administration of NaVP in preg-
nant mice can result in various cardiac abnormalities in
fetal hearts, which is likely associated with an inhibition
of histone deacetylase without altering the transcription
of this enzyme.
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